Immunocore Ltd has secured $130 million in Series B funding from new and existing investors to progress its portfolio of biologic drugs for cancer, infection and autoimmune disease. The company’s technology involves engineering T cell receptors and linking them to an antibody fragment that can activate the immune system to kill a cancer or a viral cell. Proceeds from the offering will enable to company to advance two wholly owned clinical stage programmes for chronic hepatitis B and a compound targeting PRAME, an antigen expressed on a wide range of tumours.
